Possible Benefit of Angiotensin II Receptor Blockers in COVID-19 Patients: A Case Series
Introduction . Dysfunction in the renin-angiotensin-aldosterone system (RAAS) has been observed in patients with coronavirus disease 2019 (COVID-19). It is presumed that the effect of reducing interleukin-6 (IL-6) levels by angiotensin II receptor blockers (ARBs) by RAAS modulation. We investigated...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publications
2021-05-01
|
| Series: | Journal of the Renin-Angiotensin-Aldosterone System |
| Online Access: | https://doi.org/10.1155/2021/9951540 |
| _version_ | 1797271635422609408 |
|---|---|
| author | Su Jin Lee Taehwa Kim Woo Hyun Cho Doosoo Jeon Seungjin Lim |
| author_facet | Su Jin Lee Taehwa Kim Woo Hyun Cho Doosoo Jeon Seungjin Lim |
| author_sort | Su Jin Lee |
| collection | DOAJ |
| description | Introduction . Dysfunction in the renin-angiotensin-aldosterone system (RAAS) has been observed in patients with coronavirus disease 2019 (COVID-19). It is presumed that the effect of reducing interleukin-6 (IL-6) levels by angiotensin II receptor blockers (ARBs) by RAAS modulation. We investigated changes in angiotensin II and IL-6 levels in four COVID-19 patients treated with ARBs. Case Presentation . Cases 1 and 2 were who had not received ARBs before and were newly administered ARBs. Case 3 restarted ARBs after discontinuation for 7 days, and case 4 received an increased dose of ARBs. The mean in angiotensin II levels (607.5 pg/mL, range: 488–850 pg/mL, reference range < 100 pg / mL ), C-reactive protein (CRP) (10.58 mg/dL, range 4.45-18.05 mg/dL), and IL-6 (55.78 pg/mL, range: 12.86–144.82 pg/mL, reference range < 7 pg / mL ) was observed at the admission in all patients. Upon clinical improvement, the mean decrease in CRP (1.02 mg/dL, range 0.06-3.78 mg/dL) and IL-6 (5.63 pg/mL, range 0.17-20.87 pg/mL) was observed in all patients. Conversely, angiotensin II levels gradually increased. Conclusion . This report supports the potential benefit of ARBs to improve the clinical outcomes of COVID-19 patients by controlling RAAS dysfunction. |
| first_indexed | 2024-03-07T14:07:22Z |
| format | Article |
| id | doaj.art-e53ecd5aaf494941b352e1f62876fea9 |
| institution | Directory Open Access Journal |
| issn | 1752-8976 |
| language | English |
| last_indexed | 2024-03-07T14:07:22Z |
| publishDate | 2021-05-01 |
| publisher | SAGE Publications |
| record_format | Article |
| series | Journal of the Renin-Angiotensin-Aldosterone System |
| spelling | doaj.art-e53ecd5aaf494941b352e1f62876fea92024-03-06T20:05:48ZengSAGE PublicationsJournal of the Renin-Angiotensin-Aldosterone System1752-89762021-05-01202110.1155/2021/9951540Possible Benefit of Angiotensin II Receptor Blockers in COVID-19 Patients: A Case SeriesSu Jin Lee0Taehwa Kim1Woo Hyun Cho2Doosoo Jeon3Seungjin Lim4 Introduction . Dysfunction in the renin-angiotensin-aldosterone system (RAAS) has been observed in patients with coronavirus disease 2019 (COVID-19). It is presumed that the effect of reducing interleukin-6 (IL-6) levels by angiotensin II receptor blockers (ARBs) by RAAS modulation. We investigated changes in angiotensin II and IL-6 levels in four COVID-19 patients treated with ARBs. Case Presentation . Cases 1 and 2 were who had not received ARBs before and were newly administered ARBs. Case 3 restarted ARBs after discontinuation for 7 days, and case 4 received an increased dose of ARBs. The mean in angiotensin II levels (607.5 pg/mL, range: 488–850 pg/mL, reference range < 100 pg / mL ), C-reactive protein (CRP) (10.58 mg/dL, range 4.45-18.05 mg/dL), and IL-6 (55.78 pg/mL, range: 12.86–144.82 pg/mL, reference range < 7 pg / mL ) was observed at the admission in all patients. Upon clinical improvement, the mean decrease in CRP (1.02 mg/dL, range 0.06-3.78 mg/dL) and IL-6 (5.63 pg/mL, range 0.17-20.87 pg/mL) was observed in all patients. Conversely, angiotensin II levels gradually increased. Conclusion . This report supports the potential benefit of ARBs to improve the clinical outcomes of COVID-19 patients by controlling RAAS dysfunction.https://doi.org/10.1155/2021/9951540 |
| spellingShingle | Su Jin Lee Taehwa Kim Woo Hyun Cho Doosoo Jeon Seungjin Lim Possible Benefit of Angiotensin II Receptor Blockers in COVID-19 Patients: A Case Series Journal of the Renin-Angiotensin-Aldosterone System |
| title | Possible Benefit of Angiotensin II Receptor Blockers in COVID-19 Patients: A Case Series |
| title_full | Possible Benefit of Angiotensin II Receptor Blockers in COVID-19 Patients: A Case Series |
| title_fullStr | Possible Benefit of Angiotensin II Receptor Blockers in COVID-19 Patients: A Case Series |
| title_full_unstemmed | Possible Benefit of Angiotensin II Receptor Blockers in COVID-19 Patients: A Case Series |
| title_short | Possible Benefit of Angiotensin II Receptor Blockers in COVID-19 Patients: A Case Series |
| title_sort | possible benefit of angiotensin ii receptor blockers in covid 19 patients a case series |
| url | https://doi.org/10.1155/2021/9951540 |
| work_keys_str_mv | AT sujinlee possiblebenefitofangiotensiniireceptorblockersincovid19patientsacaseseries AT taehwakim possiblebenefitofangiotensiniireceptorblockersincovid19patientsacaseseries AT woohyuncho possiblebenefitofangiotensiniireceptorblockersincovid19patientsacaseseries AT doosoojeon possiblebenefitofangiotensiniireceptorblockersincovid19patientsacaseseries AT seungjinlim possiblebenefitofangiotensiniireceptorblockersincovid19patientsacaseseries |